文献速递神经免疫神经肌肉病

全身型重症肌无力泼尼松减量方案随机对照试验

Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

这项多中心单盲随机试验比较泼尼松缓慢减量与快速减量方案,共纳入117例中重度全身型重症肌无力患者,所有患者合用硫唑嘌呤。快速减量组达到主要结局的比例显著更高(39% vs 9%),且1年内平均节省泼尼松1898 mg,严重不良事件无显著差异。

要点

  • 快速减量组12个月无泼尼松达微小表现状态且15个月无复发的比例更高(39% vs 9%,RR 3.61)。

核心结论

  • 对于需要高剂量泼尼松联合硫唑嘌呤的中重度全身型重症肌无力患者,快速减量方案可行、耐受良好且结局良好。

研究设计与样本

  • 多中心、平行、单盲随机临床试验,2009年6月1日至2013年7月31日在法国7个专科中心开展。
  • 共评估2291例成人患者,最终随机纳入117例(缓慢减量组58例,快速减量组59例)。
  • 纳入标准为确诊的中重度全身型重症肌无力;所有患者均使用硫唑嘌呤,最大剂量3 mg/kg/d。

主要发现

  • 快速减量组达到主要结局的比例为39%(23例),缓慢减量组为9%(5例),校正中心和胸腺切除术后风险比3.61(95%CI 1.64-7.97,P<.001)。

关键数值与推荐

  • 缓慢减量方案:泼尼松隔日剂量逐渐增至1.5 mg/kg,达到微小表现状态后缓慢减量。
  • 快速减量方案:立即每日给予高剂量泼尼松0.75 mg/kg,病情改善后早期快速减量。
  • 主要结局为12个月时无泼尼松的微小表现状态且15个月时无临床复发。

临床怎么用

  • 在中重度全身型重症肌无力需高剂量泼尼松联合硫唑嘌呤时,可考虑快速减量方案以减少激素累积剂量。
  • 快速减量方案未增加严重不良事件风险,但仍需个体化评估和监测。

局限性

  • 样本量较小(共117例),可能影响结果的精确性和外推性。
  • 研究为单盲设计,可能存在实施偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The tapering of prednisone therapy in generalized myasthenia gravis (MG) presents a therapeutic dilemma; however, the recommended regimen has not yet been validated. OBJECTIVE: To compare the efficacy of the standard slow-tapering regimen of prednisone therapy with a rapid-tapering regimen. DESIGN: From June 1, 2009, to July 31, 2013, a multicenter, parallel, single-blind randomized trial was conducted to compare 2 regimens of prednisone tapering. Data analysis was conducted from February 18, 2019, to January 23, 2020. A total of 2291 adults with a confirmed diagnosis of moderate to severe generalized MG at 7 specialized centers in France were assessed for eligibility. INTERVENTIONS: The slow-tapering arm included a gradual increase of the prednisone dose to 1.5 mg/kg every other day and a slow decrease once minimal manifestation status of MG was attained. The rapid-tapering arm consisted of immediate high-dose daily administration of prednisone, 0.75 mg/kg, followed by an earlier and rapid decrease once improved MG status was attained. Azathioprine, up to a maximum dose of 3 mg/kg/d, was prescribed for all participants. MAIN OUTCOMES AND MEASURES: The primary outcome was attainment of minimal manifestation status of MG without prednisone at 12 months and without clinical relapse at 15 months. Intention-to-treat analysis was conducted. RESULTS: Of the 2291 patients assessed, 2086 did not fulfill the inclusion criteria, 87 declined to participate, and 1 patient registered after trial closure. A total of 117 patients (58 in the slow-tapering arm and 59 in the rapid-tapering arm) were selected for inclusion by MG specialists and were randomized. The population included 62 men (53%); median age was 65 years (interquartile range, 35-69 years). The proportion of patients having met the primary outcome was higher in the rapid- vs slow-tapering arm (23 [39%] vs 5 [9%]), with a risk ratio of 3.61 (95% CI, 1.64-7.97; P < .001) after adjusting for center and thymectomy. The rapid-tapering regimen allowed sparing of a mean of 1898 mg (95% CI, -3121 to -461 mg) of prednisone over 1 year (ie, 5.3 mg/d per patient, P = .03). The number of serious adverse events did not differ significantly between the slow- vs rapid-tapering group (13 [22%] vs 21 [36%], P = .15). CONCLUSIONS AND RELEVANCE: In patients with moderate to severe generalized MG who require high-dose prednisone with azathioprine therapy, rapid tapering of prednisone appears to be feasible, well tolerated, and associated with a good outcome. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00987116.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Sharshar T, Porcher R, Demeret S, et al. Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33555314. doi:10.1001/jamaneurol.2020.5407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。